Should you buy this stock after sales rose 20% in Q3?

Is a 20% rise in sales the beginning of big things for this company?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Third quarter results released today for speciality chemicals maker Croda (LSE: CRDA) saw sales jump a full 20.1% year-on-year to hit £315m. Unfortunately, management was very upfront about the fact that “with over 95% of sales outside the UK, this largely reflected favourable currency translation, with the impact of weaker sterling increasing sales by 17.6%.”

Stripping out the effects of the weaker pound, constant currency sales did rise 2.5% year-on-year due to the positive effects of an acquisition in Croda’s crop care division. However, core underlying sales dropped 2.5% on the back of falling sales of a major generic pharmaceutical ingredient.

Sales compressing is never a good sign and will be worth watching in the coming quarters. But, if underlying sales return to growth then Croda becomes very attractive. A major reason is that the company is well diversified by designing chemicals for everything from haircare, lipstick and sunscreen to seed treatments and environmentally-friendly paint coatings.

Developing and selling these products is also a very capital light business, which produces significant free cash flow. And, a cost-conscious management team and increasing sales of patented products allowed operating margins to improve to 25.7% in H1.

The impressive cash generated by these margins and tight control over capex allow Croda to make targeted acquisitions without resorting to high leverage. At the end of July the company’s net debt-to-EBITDA ratio was only 1.3, a very healthy level for such a cash generative business. This is allowing dividends to increase substantially, although a long rally in share prices means they only yield 2%. Croda is certainly an attractive company, and I believe the shares are worth following in the coming quarters.

Worth a look?

While Croda’s products focus on retail applications, another of the FTSE’s leading industrial firms, Elementis (LSE: ELM), concentrates on industrial applications for oil rigs, cargo ships and construction materials. Elementis has been hit hard by the downturn in the oil & gas industry, with revenue from this key segment down 26% in the first half of the year.

This dramatic fall in sales drove overall group revenue down by 7% year-on-year and led to operating margins collapsing from 19% to 15%. A decrease in oilfield activity isn’t the only headwind facing Elementis as the strong US dollar has negatively impacted sales in its chromium division and forced the company to issue a profit warning in June.

That said, its core business is quite impressive. Its operations still spin off significant cash, which management has no qualms about returning to shareholders due to having no debt. With net cash at the end of June standing at $37.5m, the company was able to maintain interim dividends even as earnings fell.

The twin headwinds facing Elementis, a struggling oil & gas sector and strong US dollar, aren’t about to stop any time soon. However, with a great underlying business, shares trading at a relatively sane level and dividends already yielding 3.3%, now could be the time for contrarian investors to take a closer look.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has recommended Elementis. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »